Send the link below via email or IMCopy
Present to your audienceStart remote presentation
- Invited audience members will follow you as you navigate and present
- People invited to a presentation do not need a Prezi account
- This link expires 10 minutes after you close the presentation
- A maximum of 30 users can follow your presentation
- Learn more about this feature in our knowledge base article
Do you really want to delete this prezi?
Neither you, nor the coeditors you shared it with will be able to recover it again.
Make your likes visible on Facebook?
You can change this under Settings & Account at any time.
SWOT Analysis - Roche
Transcript of SWOT Analysis - Roche
Roche begins marketing biochemicals (amino acids, proteins, cardiac glycosides, vitamins and hormones). 1915-1927 The time of crisis Roche managed to overcome the crisis due to the success of vitamins. It becomes the leading supplier of vitamins A, B1, B2, E e K1. 1928-1944 Vitamin boost Vitamin output increases and new production locations strengthens Roche's position as one of the main producers of vitamins. To avoid a strong dependency on vitamins Roche intensifies pharmaceutical research. 1945-1964 Streamlining Roche branches out into new markets spanning the whole spectrum of healthcare.
After an alignment of the company's structure Roche is left with four core business divisions: pharmaceuticals, vitamins and fine chemicals, diagnostics, and flavours and fragrances. 1965-1990 Diversification and Reform Roche acquires the world-wide marketing rights to PCR.
Roche's drugs tackle HIV (Invirase, Valcyte, Fuzeon) and Cancer (Herceptin, MabThera).
The company launches new diagnostics tests and equipment 1991-2000 Innovative developments Syntex Corporation Boehringer Mannheim Roche sharpens its focus on two core businesses - Pharmaceuticals and Diagnostics 2000-2006 Company restructure and Focus on Biotech Givaudan Vitamins & fine chemicals Consumer Health Division Nippon Roche Chugai Chugai Pharmaceuticals Disetronic GlycArt Biotechnology 2007-2013 Moving towards Personalized Healthcare NimbleGen BioVeris Genentech COMPANY SUMARY Core businesses Mission Vision Develop treatments and tests tailored to the needs of specific patient populations, improving effectiveness, safety and cost-effectiveness Business model Personalized healthcare Research-focused healthcare Discover, develop and provide innovative diagnostic and therapeutic products and services that deliver significant benefits to patients and healthcare professionals Values Commitment to scientific rigor and unassailable ethics. Work towards excellence with the intent to provide access to medical innovations for all. Excellence in science R&D driven company COMPANY SUMARY Strategic priorities Patients in need Personalized healthcare Excellence in science Innovative pricing models Stakeholder value SALES R&D PIPELINE ROCHE AT A GLANCE SWOT ANALYSIS Basel, Switzerland F. Hoffmann-La Roche & Co. The founding year Julien Boisdron Jorge Correia Medical Director Institutional Relations Received approvals for 2 new cancer medicines
Delivered positive results in 11 out of 14 late-stage clinical trials
Continued clinical development of 72 promising new molecular entities
Launched 55 diagnostic products in key markets In 2012 WEAKNESSES STRENGTHS Robust portfolio THREATS OPPORTUNITIES Includes several blockbusters such as Mabthera/Rituxan, Herceptin, Avastin, etc. Young portfolio Most patent expire in 5 to 8 years no.1 in BIOPHARMA (revenues) and R&D (expenditures) Medically differentiated products and services Each product/service has a strong competitive position Competitive compensations and benefits for employees Strong pipeline Innovation created by betting on ideas Long-term perspectives are not sacrificed by short-sighted cost cuts Success driven by innovation Fueled by several partners and 4 autonomous research centers Strategic partnerships Patents of some blockbusters are expiring Recent drawbacks Company structure Metabolic/Cardiovascular areas
Dalcetrapib Only 18.5% of people in key positions are women; Roche's 2014 goal is merely 20% Mabthera/Rituxan - 2013 (EU), 2016 (US)
Herceptin - 2014 (EU), 2019 (US) Pipeline Underdeveloped areas such as Virology, infectious diseases and Neurosciences
Environmental policy Pollution levels - energy consumption from air travel increased by 10.6% (2012) "Introduce a better innovator in the market to replace the previous one" Biosimilar competition Price pressure Tightening regulatory approvals Legislation encourages comparison of medical treatments on the basis of safety, efficacy and additionally cost Mabthera/Rituxan Growing bargaining power of intermediaries Hospitals Changes in how patients access medicine "Lower the price of the innovator" Celltrion
Sandoz "The company bets on ideas. We haven't found the right opportunity to shift our pipeline towards those areas" Herceptin Pfizer
Novartis "Introduce a better innovator in the market to substitute the previous one" Herceptin Kadcyla (T-DM1) Mabthera/Rituxan Obinutuzumab (GA101) Transtuzumab + cytotoxic
Aproved by the FDA (2013)
Combined therapy with Perjeta The 1st glycoengineered humanized anti-CD20 mAb finished phase III Public policies and budgetary challenges Reimbursement cuts for Diabetes Care in Europe Unexplored market segments for existing products Development of new Antibody-drug conjugates (ADCs) In traditional markets On trials for additional indications:
Herceptin (1) Delivered 11 positive results out of 14 late-stage studies in 2012 2 new cancer drugs launched in 2012 Perjeta (breast cancer) and Erivedge (advanced basal cell carcinoma), both with a positive initial uptake Lucentis for diabetic macular edema Lower public research funding Decline in sales in the Applied Science business Emerging markets (Latin America, Asia, and South Africa) Replicate the success of T-DM1 in other types of cancer Focus in products, such as high-value medicines and diagnostic tests
Focus in areas with unmet efficient diagnostics and treatments and with a growing rate due to an ageing population Stakeholder engagement / Community involvement Work from the outside in "In Portugal, INFARMED hasn't approved any new medicine in the last 2 years" Broad external network - strong research capabilities TOP SELLING PRODUCTS Pharmaceuticals Diagnostics MabThera/Rituxan
6.707 millions CHF Herceptin
Blood glucose monitoring
2.321 Cobas Integra
1.514 Cobas TaqMan
Avanced tissue staining
518 Combination of pharmaceuticals and diagnostics leads to a more efficient development and helps to achieve the goal of fitting treatments to patients In 2013 FDA approved Kadcyla (T-DM1) - already included in NCCN guidelines
Perjeta was approved in EU and launched in the US
Emerging pipeline to secure Mabthera/Rituxan hematology franchise (GA101; Bcl-2) September 30, 2012 2013 Q1 Pipeline milestones April 2013 "So far the products have successfully shown their benefit/cost ratio" "Roche focuses in developing highly differentiated and effective treatments to patients. We provide personalized healthcare by pinpointing exactly which patients will respond to a particular therapy" "The trials must show that the product delivers value to patients.
So far the products have successfully shown their benefit/cost ratio" GA101
T-DM1 "Dalcetrapib was a high-risk project. We are disappointed by the fact that this drug didn't provide benefit to the patients in our study" Ilumina rejected Roche’s takeover offer Considered a supersector leader by the Dow Jones sustainability index (2012) Roche boasts a strong pipeline involving new molecular entities and line extensions for its existing products Ana Filipa Louro | Helena Perdigão | Matilde Trabuco In oncology - a lot of products being developed for the same target